Drug Profile
House dust mite allergy immunotherapy - Laboratorios LETI
Alternative Names: Depigoid Dermatophagoides pteronyssinus/Dermatophagoides farinae; DP/MG/14-1; DP/MG/14-2Latest Information Update: 05 Apr 2021
Price :
$50
*
At a glance
- Originator Laboratorios LETI
- Class Allergens; Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Allergic rhinitis
- No development reported Allergic asthma
Most Recent Events
- 05 Apr 2021 No development reported - Phase-II for Allergic asthma (In the elderly, In adults) in Spain (SC)
- 01 Mar 2019 Discontinued - Phase-II for Allergic asthma (In adolescents, In children) in Spain (SC) (NCT00622362)
- 01 Mar 2019 Laboratorios LETI terminates a phase II trial in Allergic asthma in Spain due to low recruitment (SC) (NCT00622362)